These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 1973396)

  • 1. Treatment of non-steroidal anti-inflammatory drug induced enteropathy.
    Bjarnason I; Hopkinson N; Zanelli G; Prouse P; Smethurst P; Gumpel JM; Levi AJ
    Gut; 1990 Jul; 31(7):777-80. PubMed ID: 1973396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonsteroidal antiinflammatory drug-induced small intestinal inflammation and blood loss. Effects of sulfasalazine and other disease-modifying antirheumatic drugs.
    Hayllar J; Smith T; Macpherson A; Price AB; Gumpel M; Bjarnason I
    Arthritis Rheum; 1994 Aug; 37(8):1146-50. PubMed ID: 7914409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of non-steroidal anti-inflammatory drugs on the human small intestine.
    Bjarnason I; Zanelli G; Prouse P; Williams P; Gumpel MJ; Levi AJ
    Drugs; 1986; 32 Suppl 1():35-41. PubMed ID: 3780475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood and protein loss via small-intestinal inflammation induced by non-steroidal anti-inflammatory drugs.
    Bjarnason I; Zanelli G; Prouse P; Smethurst P; Smith T; Levi S; Gumpel MJ; Levi AJ
    Lancet; 1987 Sep; 2(8561):711-4. PubMed ID: 2888943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonsteroidal antiinflammatory drug-induced enteropathy and severe chronic anemia in a patient with rheumatoid arthritis.
    Davies NM; Jamali F; Skeith KJ
    Arthritis Rheum; 1996 Feb; 39(2):321-4. PubMed ID: 8849386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variables affecting efficacy and toxicity of sulphasalazine in rheumatoid arthritis. A review.
    Pullar T; Capell HA
    Drugs; 1986; 32 Suppl 1():54-7. PubMed ID: 2877854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treating rheumatoid arthritis early with disease modifying drugs reduces joint damage: a randomised double blind trial of sulphasalazine vs diclofenac sodium.
    Choy EH; Scott DL; Kingsley GH; Williams P; Wojtulewski J; Papasavvas G; Henderson E; Macfarlane D; Erhardt C; Young A; Plant MJ; Panayi GS
    Clin Exp Rheumatol; 2002; 20(3):351-8. PubMed ID: 12102471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long term outcome of treatment with sulphasalazine in rheumatoid arthritis.
    Situnayake RD; McConkey B
    Drugs; 1986; 32 Suppl 1():71-2. PubMed ID: 2877857
    [No Abstract]   [Full Text] [Related]  

  • 9. Sulphasalazine therapy in rheumatoid arthritis. A two-year study and follow-up of clinical results.
    Georgescu C
    Rom J Intern Med; 1992; 30(2):127-32. PubMed ID: 1353901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sulphasalazine in the long term management of rheumatoid arthritis.
    Bax DE; Amos RS
    Drugs; 1986; 32 Suppl 1():73-6. PubMed ID: 2877858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-Aminosalicylic acid or sulphapyridine. Which is the active moiety of sulphasalazine in rheumatoid arthritis?
    Taggart AJ; Neumann VC; Hill J; Astbury C; Le Gallez P; Dixon JS
    Drugs; 1986; 32 Suppl 1():27-34. PubMed ID: 2877851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Side effect profile of 200 patients with inflammatory arthritides treated with sulphasalazine.
    Farr M; Scott DG; Bacon PA
    Drugs; 1986; 32 Suppl 1():49-53. PubMed ID: 2877853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sulphasalazine in the treatment of rheumatoid arthritis.
    Pelísková Z; Vácha J; Trnavský K
    Z Rheumatol; 1985; 44(6):263-6. PubMed ID: 2869625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonsteroidal peptic damage in rheumatoid patients receiving second-line drugs.
    Taha AS; Capell HA; Sturrock RD; Russell RI
    Am J Gastroenterol; 1991 Nov; 86(11):1588-91. PubMed ID: 1683150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sulphasalazine induced three-week syndrome.
    Suresh R; Gupta S; Sathananthan R
    J Clin Rheumatol; 2009 Sep; 15(6):311-2. PubMed ID: 19734741
    [No Abstract]   [Full Text] [Related]  

  • 16. Sulphasalazine for rheumatoid arthritis. Studies on dose, acetylator phenotype and efficacy.
    Amos RS; Bax DE; Greaves MS
    Drugs; 1986; 32 Suppl 1():58. PubMed ID: 2877855
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparison of white blood cell dyscrasias during sulphasalazine therapy of rheumatoid arthritis and inflammatory bowel disease.
    Capell HA; Pullar T; Hunter JA
    Drugs; 1986; 32 Suppl 1():44-8. PubMed ID: 2877852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-tumour necrosis factor agents reduce non-steroidal anti-inflammatory drug-induced small bowel injury in rheumatoid arthritis patients.
    Watanabe T; Tanigawa T; Shiba M; Nadatani Y; Nagami Y; Sugimori S; Yamagami H; Watanabe K; Tominaga K; Fujiwara Y; Koike T; Arakawa T
    Gut; 2014 Mar; 63(3):409-14. PubMed ID: 23697473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Symposium on enteric-coated sulphasalazine in rheumatoid arthritis. Proceedings of a symposium. London, December 6, 1985.
    Drugs; 1986; 32 Suppl 1():1-80. PubMed ID: 2877848
    [No Abstract]   [Full Text] [Related]  

  • 20. A case of sulindac-induced enteropathy resulting in jejunal perforation.
    Yoon KH; Ng SC
    Ann Acad Med Singap; 1998 Jan; 27(1):116-9. PubMed ID: 9588286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.